中国血液净化

中国血液净化 ›› 2022, Vol. 21 ›› Issue (07): 456-468.doi: 10.3969/j.issn.1671-4091.2022.07.001

• 贫血专题 •    下一篇

红细胞生成素在肾纤维化中的作用及机制研究

张 祥   陈红波    

  1. 浙江中医药大学第一临床医学院； 浙江中医药大学附属第一医院肾病科
  • 收稿日期:2022-03-24 修回日期:2022-05-05 出版日期:2022-07-12 发布日期:2022-07-12
  • 通讯作者: chenhb521@126.com E-mail:陈红波
  • 基金资助:
    浙江省自然科学基金(LY18H290005)

The effects of erythropoietin on renal fibrosis

  1. The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China; 2The first affiliated hospital,
    Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou 310006, China
  • Received:2022-03-24 Revised:2022-05-05 Online:2022-07-12 Published:2022-07-12

PDF

148

摘要： 肾纤维化是大多数慢性肾脏病(chronic kidney disease，CKD)进展至终末期的共同病理表
现，其严重程度与CKD的预后密切相关。近年来，相关研究发现红细胞生成素(erythropoietin，EPO)与
肾纤维化的发生发展关系密切。EPO作为一种红细胞刺激因子，外源性补充EPO不仅可以治疗肾性贫血，
还可以有效防治肾纤维化，从而改善肾功能。本文将EPO在肾纤维化中的作用及可能的抗纤维化作用机
制进行综述，以期为防治肾纤维化提供新的治疗思路。

关键词: 红细胞生成素, 肾纤维化, REP细胞, 红细胞生成素受体

Abstract: Renal fibrosis is a common end-stage pathological manifestation of chronic kidney disease
(CKD), and its severity is closely related to the prognosis of CKD. In recent years, some studies have found
that erythropoietin (EPO) is closely associated with the occurrence and development of renal fibrosis. As a regulator of red blood cell production, exogenous EPO supplementation can not only improve renal anemia, but
also improve renal function and effectively prevent and treat renal fibrosis. Therefore, this paper reviews the
role of EPO in renal fibrosis and its anti-fibrosis mechanism, providing new ideas for the application of EPO
in the treatment of renal fibrosis in the future.

Key words: Erythropoietin, Renal fibrosis, renal EPO-producing cells, EPOR receptor

中图分类号: